RITUXIMAB
Drug
Sandoz Inc.
Total Payments
$196,302
Transactions
67
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $17,533 | 24 | 1 |
| 2017 | $178,769 | 43 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $191,586 | 66 | 97.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,716 | 1 | 2.4% |
Payments by Type
Research
$191,586
66 transactions
General
$4,716
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE PK, PD, SAFETY AND EFFICACY OF GP2013 AND RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY OR INTOLERANT TO STANDARD DMARDS AND UP TO THREE ANTI-TNF THERAPIES | Sandoz Inc. | $96,368 | 0 |
| A RANDOMIZED, DOUBLE- BLIND, CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF TRANSITIONING TO GP2013 OR RE-TREATMENT WITH RITUXAN? OR MABTHERA? IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PREVIOUSLY TREATED WITH RITUXAN? OR MABTHERA? | Sandoz Inc. | $86,079 | 0 |
| A RANDOMIZED, DOUBLE- BLIND, CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF TRANSITIONING TO GP2013 OR RE-TREATMENT WITH RITUXAN OR MABTHERA IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PREVIOUSLY TREATED WITH RITUXAN OR MABTHERA | Sandoz Inc. | $9,139 | 0 |
Top Doctors Receiving Payments for RITUXIMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charleston, SC | $191,586 | 66 |
| , MD | Internal Medicine | New York, NY | $4,716 | 1 |
Ad
Manufacturing Companies
- Sandoz Inc. $196,302
Product Information
- Type Drug
- Total Payments $196,302
- Total Doctors 1
- Transactions 67
About RITUXIMAB
RITUXIMAB is a drug associated with $196,302 in payments to 1 healthcare providers, recorded across 67 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2018. In 2018, $17,533 was paid across 24 transactions to 1 doctors.
The most common payment nature for RITUXIMAB is "Unspecified" ($191,586, 97.6% of total).
RITUXIMAB is associated with 3 research studies, including "A RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE PK, PD, SAFETY AND EFFICACY OF GP2013 AND RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY OR INTOLERANT TO STANDARD DMARDS AND UP TO THREE ANTI-TNF THERAPIES" ($96,368).